Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Yoshizaki, Takayuki ^a,b   Motomura, Wataru ^b   Tanno, Sachie ^b   Kumei, Shima ^b   Yoshizaki, Yumiko ^a   Tanno, Satoshi ^b   Okumura, Toshikatsu ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CIGLITAZONE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JE 11; MESSENGER RNA; NEUROPILIN 1; TROGLITAZONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VASCULOTROPIN A;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; DRUG EFFECT; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL PROLIFERATION; CULTURE MEDIUM; LUNG TUMOR; METABOLISM; PHOSPHORYLATION; PRENATAL DEVELOPMENT; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; NEUROPILIN-1; PHOSPHORYLATION; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949429691     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-22     Document Type: Article

References (37)

1. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. BM Spiegelman, Diabetes 1998 47 507 514 10.2337/diabetes.47.4.507 9568680
2. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. E Elstner C Muller K Koshizuka EA Williamson D Park H Asou P Shintaku JW Said D Heber HP Koeffler, Proceedings of the National Academy of Sciences of the United States of America 1998 95 8806 8811 10.1073/pnas.95.15.8806 9671760 (Pubitemid 28350570)
3. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. KG Lambe JD Tugwood, European Journal of Biochemistry 1996 239 1 7 10.1111/j.1432-1033.1996. 0001u.x 8706692
4. Terminal differentiation of human breast cancer through PPAR gamma. E Mueller P Sarraf P Tontonoz RM Evans KJ Martin M Zhang C Fletcher S Singer BM Spiegelman, Molecular Cell 1998 1 465 470 10.1016/S1097-2765(00)80047-7 9660931 (Pubitemid 128378895)
5. Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. N Takahashi T Okumura L Motomura Y Fujimoto I Kawabata Y Kohgo, Febs Letters 1999 455 135 139 10.1016/S0014-5793(99)00871-6 10428487 (Pubitemid 29322796)
6. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. AP Heaney M Fernando WH Yong S Melmed, Nature Medicine 2002 8 1281 1287 10.1038/nm784 12379847 (Pubitemid 35373561)
7. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. VG Keshamouni RC Reddy DA Arenberg B Joel VJ Thannickal GP Kalemkerian TJ Standiford, Oncogene 2004 23 100 108 10.1038/sj.onc.1206885 14712215 (Pubitemid 38142244)
8. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. T Kubota K Koshizuka EA Williamson H Asou JW Said S Holden I Miyoshi HP Koeffler, Cancer Research 1998 58 3344 3352 9699665 (Pubitemid 28371075)
9. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells. W Motomura T Okumura N Takahashi T Obara Y Kohgo, Cancer Research 2000 60 5558 5564 11034103
10. PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. LL Peeters JL Vigne MK Tee D Zhao LL Waite RN Taylor, Angiogenesis 2005 8 373 379 10.1007/s10456-005-9027-4 16400517 (Pubitemid 43312272)
11. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. T Shigeto Y Yokoyama B Xin H Mizunuma, Oncology Reports 2007 18 833 840 17786343
12. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. SK Vijay M Mishra H Kumar K Tripathi, Acta Diabetologica 2009 46 27 33 10.1007/s00592-008-0054-7 18758684
13. Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model. M Jin Y Saekusa Y Dewa J Nishimura S Matsumoto M Shibutani K Hasumi K Mitsumori, Archives of Toxicology 2009 83 173 181 10.1007/s00204-008-0335-5 18597072
14. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. V Chintalgattu GS Harris SA Akula LC Katwa, Cardiovascular Research 2007 74 140 150 10.1016/j.cardiores.2007.01.010 17320065 (Pubitemid 46366953)
15. Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy. N Suwaki H Masuyama A Masumoto N Takamoto Y Hiramatsu, Placenta 2007 28 315 323 10.1016/j.placenta. 2006.04.002 16753211 (Pubitemid 46505940)
16. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. HC Yang LJ Ma J Ma AB Fogo, Kidney International 2006 69 1756 1764 10.1038/sj.ki.5000336 16598202 (Pubitemid 43739202)
17. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. T Tanaka Y Fukunaga H Itoh K Doi J Yamashita TH Chun M Inoue K Masatsugu T Saito N Sawada, et al. European Journal of Pharmacology 2005 508 255 265 10.1016/j.ejphar.2004.10.056 15680279 (Pubitemid 40169927)
18. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. M Emoto T Anno Y Sato K Tanabe S Okuya Y Tanizawa A Matsutani Y Oka, Diabetes 2001 50 1166 1170 10.2337/diabetes.50.5.1166 11334422 (Pubitemid 32374549)
19. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. K Yamakawa M Hosoi H Koyama S Tanaka S Fukumoto H Morii Y Nishizawa, Biochemical and Biophysical Research Communications 2000 271 571 574 10.1006/bbrc.2000.2665 10814503 (Pubitemid 30444669)
20. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. S Singhal A Vachani D Antin-Ozerkis LR Kaiser SM Albelda, Clinical Cancer Research 2005 11 3974 3986 10.1158/1078-0432.CCR-04-2661 15930332 (Pubitemid 40791561)
21. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. S Soker S Takashima HQ Miao G Neufeld M Klagsbrun, Cell 1998 92 735 745 10.1016/S0092-8674(00)81402-6 9529250 (Pubitemid 28155313)
22. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. JA Forsythe BH Jiang NV Iyer F Agani SW Leung RD Koos GL Semenza, Molecular and Cellular Biology 1996 16 4604 4613 8756616 (Pubitemid 26272112)
23. The biology of VEGF and its receptors. N Ferrara HP Gerber J LeCouter, Nature Medicine 2003 9 669 676 10.1038/nm0603-669 12778165 (Pubitemid 36749215)
24. Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF. C Piossek J Schneider-Mergener M Schirner E Vakalopoulou L Germeroth KH Thierauch, Journal of Biological Chemistry 1999 274 5612 5619 10.1074/jbc.274.9.5612 10026178 (Pubitemid 29109212)
25. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 alpha. Z Arany SY Foo YH Ma JL Ruas A Bommi-Reddy G Girnun M Cooper D Laznik J Chinsomboon SM Rangwala, et al. Nature 2008 451 1008 U1008 10.1038/nature06613 18288196
26. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Q Pan Y Chanthery WC Liang S Stawicki J Mak N Rathore RK Tong J Kowalski SF Yee G Pacheco, et al. Cancer Cell 2007 11 53 67 10.1016/j.ccr.2006.10.018 17222790 (Pubitemid 46054517)
27. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. MY Li TW Lee TSK Mok TD Warner APC Yim GG Chen, Journal of Cellular Biochemistry 2005 96 760 774 10.1002/jcb.20474 16149072
28. Tissue factor expression in non-small cell lung cancer: Relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. S Regina J Rollin C Blechet S Iochmann P Reverdiau Y Gruel, Journal of Thoracic Oncology 2008 3 689 697 10.1097/JTO.0b013e31817c1b21 18594312
29. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. M Li Y Hui H Chai WE Fisher XP Wang FC Brunicardi QZ Yao CY Chen, Cancer 2004 101 2341 2350 10.1002/cncr.20634 15476280 (Pubitemid 39458692)
30. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Weidner JP Semple WR Welch J Folkman, N Engl J Med 1991 324 1 8 1701519
31. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. N Weidner PR Carroll J Flax W Blumenfeld J Folkman, American Journal of Pathology 1993 143 401 409 7688183 (Pubitemid 24058195)
32. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. DH Gorski AD Leal JS Goydos, 2003 408 418 12946796
33. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. DJ Hicklin LM Ellis, Journal of Clinical Oncology 2005 23 1011 1027 10.1200/JCO.2005.06.081 15585754 (Pubitemid 46202320)
34. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. R Govindarajan L Ratnasinghe DL Simmons ER Siegel MV Midathada L Kim PJ Kim RJ Owens NP Lang, 2007 1476 1481 17442990
35. Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism. W Zhang H Zhang L Xing, J Huazhong Univ Sci Technolog Med Sci 2006 26 36 39 16711003
36. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. MA Herve H Buteau-Lozano R Vassy I Bieche G Velasco M Pla G Perret S Mourah M Perrot-Applanat, American Journal of Pathology 2008 172 167 178 10.2353/ajpath.2008.070181 18079435 (Pubitemid 351186378)
37. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. C Stockmann A Doedens A Weidemann N Zhang N Takeda JI Greenberg DA Cheresh RS Johnson, Nature 2008 456 814 U107 10.1038/nature07445 18997773